FKHR(Phospho-Ser319) Antibody

Catalog Number:

11136

Amount:

100μg

Price:

$319

Swiss-Prot No:

Swiss-Prot: Q12778
NCBI Protein: NP_002006.2

Form of Antibody:

Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability:

Immunogen:

Peptide sequence around phosphorylation site of serine 319 (T-S-S(p)-N-A) derived from Human FKHR/FOXO1A.

Purification:

Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.

Specificity/Sensitivity:

The antibody detects endogenous level of FKHR only when phosphorylated at serine 319.

Applications:

WB IHC IF

Background:

FKHR belongs to the forkhead family of transcription factors, which are characterized by a distinct forkhead domain. It may play a role in myogenic growth and differentiation. The mammalian DAF-16-like transcription factors, FKHR, FKHRL1, and AFX, function as key regulators of insulin signaling, cell cycle progression, and apoptosis downstream of phosphoinositide 3-kinase. Gene activation through binding to insulin response sequences has been essential for mediating these functions. D-type Cyclins (in Class III) is required for FKHR mediated inhibition of cell cycle progression and transformation. FKHR gene is mapped to chromosome 13q14

Rena G, et al. (2002) EMBO J 21(9): 2263-2271.
Woods YL, et al. (2001) Biochem J355(Pt 3): 597-607.
Rena G, et al. (2001) Biochem J 354(Pt 3): 605-612.

References:

appl_detail:

Predicted MW: 78-82 kd
Western blotting: 1:500~1:1000
Immunohistochemistry: 1:50~1:100
Immunofluorescence: 1:100~1:200

Datasheet PDF